Vaxchora Shortage: What Providers and Prescribers Need to Know in 2026

As a healthcare provider recommending pre-travel cholera vaccination, you may have encountered situations where patients report difficulty locating Vaxchora (Vibrio Cholerae Cvd 103-Hgr Strain Live Antigen). This briefing provides an up-to-date overview of Vaxchora availability in 2026, the factors driving supply constraints, and practical strategies to help your patients access the vaccine.

Provider Briefing: Current State of Vaxchora

Vaxchora remains the only FDA-approved cholera vaccine available in the United States. Approved in June 2016 for adults 18-64 and expanded to ages 2-17 in 2020, it is manufactured exclusively by Emergent Travel Health Inc. (Redwood City, CA). No generic, biosimilar, or alternative cholera vaccine holds FDA approval.

Key clinical parameters:

• Indication: Active immunization against disease caused by Vibrio cholerae serogroup O1 in persons ages 2-64 traveling to cholera-affected areas
• Dosing: Single oral dose (100 mL reconstituted suspension; 50 mL for ages 2-5) administered ≥10 days before potential exposure
• Efficacy: 90.3% VE at 10 days, 79.5% VE at 3 months (challenge study data)
• Seroconversion: 93.5% (ages 18-45), 90.4% (ages 46-64), 98.5% (ages 2-17)

Supply Chain Timeline

Vaxchora has experienced periodic availability challenges since its initial approval:

• 2016: FDA approval; limited initial distribution through specialty channels
• 2017-2019: Gradual expansion of distribution; availability primarily through travel health clinics and hospital pharmacies
• 2020: Pediatric indication approved (ages 2-17); production capacity adjustments
• 2021-2023: Intermittent supply constraints reported, likely related to pandemic-era manufacturing disruptions and reduced travel demand affecting production planning
• 2024-2026: Supply has stabilized but remains concentrated in specialty distribution channels. Retail pharmacy availability continues to be limited.

Prescribing Implications

Several factors are relevant to prescribing decisions:

Timing Is Critical

Vaxchora must be administered at least 10 days before potential cholera exposure. Given the time needed to locate and obtain the vaccine, providers should discuss cholera vaccination at the earliest opportunity — ideally during the initial pre-travel consultation, 4-6 weeks before departure.

Administration Requirements

Vaxchora is reconstituted and administered in a healthcare setting:

• Buffer packet dissolved in 100 mL purified bottled water (not tap water)
• Active component packet added and stirred for ≥30 seconds
• Patient must avoid food and drink for 60 minutes before and after administration
• Must be consumed within 4 hours of reconstitution (30 minutes if sweetened)
• Medical waste disposal procedures required for all materials

Drug Interactions

Advise patients to avoid the following around the time of vaccination:

• Systemic antibiotics: May reduce vaccine effectiveness by killing the live attenuated organism
• Chloroquine: May interfere with vaccine immunogenicity

Contraindications and Limitations

• Not established as safe or effective in immunocompromised patients
• Efficacy not established in individuals with pre-existing immunity from prior cholera exposure
• Does not protect against V. cholerae serogroup O139 or non-O1 serogroups
• Not approved for patients over 64 years of age

Availability Picture in 2026

The current availability landscape can be summarized as follows:

• Travel health clinics: Most reliable source. These facilities routinely stock Vaxchora and have appropriate cold-chain and reconstitution capabilities.
• Hospital/academic pharmacies: Institutions with travel medicine or infectious disease departments frequently maintain stock.
• Retail pharmacies: CVS, Walgreens, and other major chains rarely carry Vaxchora. Special ordering is possible but may take 3-7 business days.
• Independent pharmacies: Some compounding or specialty-focused independents may carry it or order it promptly.

Cost and Access Considerations

Vaxchora's cost can be a barrier for some patients:

• Cash price: Approximately $373 per single-dose package
• Discount card pricing: ~$295 with SingleCare
• Insurance: Coverage is inconsistent. Some plans cover Vaxchora as a medical benefit when travel to a cholera-endemic area is documented. Medicare Part D and most Medicare Advantage plans do not cover it.
• No manufacturer copay card: Emergent Travel Health does not currently offer a standard patient savings program for Vaxchora.

For patients with financial concerns, providers can suggest checking NeedyMeds or RxAssist for potential assistance programs. See our patient-facing guide on saving money on Vaxchora.

Tools and Resources for Providers

Several resources can help you and your patients navigate Vaxchora access:

• Medfinder for Providers: medfinder.com/providers allows you to check medication and vaccine availability and direct patients to locations with stock.
• Emergent Travel Health: Contact the manufacturer directly for distributor information and supply updates.
• CDC Travel Health Notices: Monitor CDC.gov for cholera outbreak updates that may affect vaccine demand.
• ACIP Recommendations: Stay current with Advisory Committee on Immunization Practices guidance on cholera vaccination.

Looking Ahead

No competing cholera vaccines are currently in the FDA approval pipeline for the US market. Internationally available vaccines (Dukoral, Shanchol, Euvichol-Plus) remain non-FDA-approved. For patients who will be in countries where these vaccines are available, discussing vaccination abroad may be a reasonable contingency plan.

Providers should continue to recommend Vaxchora for appropriate patients while setting realistic expectations about the effort required to locate it.

Final Thoughts

Vaxchora's limited availability reflects the unique market dynamics of a niche travel vaccine rather than a traditional drug shortage. By initiating the vaccination conversation early, leveraging tools like Medfinder for Providers, and guiding patients to travel health clinics, you can help ensure your patients receive timely cholera protection before their trips.

For a complementary provider perspective, see our guide on how to help your patients find Vaxchora in stock.